CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS

Clinical trials for CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS trials appear

Sign up with your email to follow new studies for CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New cell therapy trial targets Tough-to-Treat cancers

Disease control Not yet recruiting

This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific marker called Claudin18.2. The main goals are to see if the treatment is safe and if it can shrink tumors. Participants will have their own immune …

Matched conditions: CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS

Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control

Last updated Mar 19, 2026 14:56 UTC

CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS

Get alerted when new CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS trials appear

New cell therapy trial targets Tough-to-Treat cancers